{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T23:14:37Z","timestamp":1793142877455,"version":"4.5.0"},"reference-count":33,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,8,19]],"date-time":"2024-08-19T00:00:00Z","timestamp":1724025600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100019779","name":"Qatar National Library","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019779","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["heartandlung.org","clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heart & Lung"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.hrtlng.2024.08.015","type":"journal-article","created":{"date-parts":[[2024,8,30]],"date-time":"2024-08-30T01:12:17Z","timestamp":1724980337000},"page":"298-304","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Safety and effectiveness of interference RNA (RNAi) based therapeutics in cardiac failure: A systematic review"],"prefix":"10.1016","volume":"68","author":[{"given":"Muhammad Nabeel","family":"Saddique","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Qadri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noor ul","family":"Ain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eesha","family":"Farhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatima","family":"Shahid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javeria","family":"Benyamin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Atif","family":"Bashir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hritvik","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2627-685X","authenticated-orcid":false,"given":"Javed","family":"Iqbal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.hrtlng.2024.08.015_bib0001","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1093\/stcltm\/szad038","article-title":"Fulfilling the promise of RNA therapies for cardiac repair and regeneration","volume":"12","author":"Giacca","year":"2023","journal-title":"Stem Cells Transl Med"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0002","doi-asserted-by":"crossref","first-page":"15514","DOI":"10.3390\/ijms232415514","article-title":"Modified mRNA therapeutics for heart diseases","volume":"23","author":"Magadum","year":"2022","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0003","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1007\/s11883-022-01007-9","article-title":"RNA therapeutics: the next generation of drugs for cardiovascular diseases","volume":"24","author":"Bejar","year":"2022","journal-title":"Curr Atheroscler Rep"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0004","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1093\/ehjcvp\/pvac052","article-title":"RNA-targeted therapeutics in cardiovascular disease: the time is now","volume":"9","author":"Krychtiuk","year":"2022","journal-title":"Eur Heart J - Cardiovasc Pharmacother"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0005","unstructured":"PRISMA statement. 2024 https:\/\/www.prisma-statement.org (accessed June 15, 2024)."},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0006","author":"Higgins","year":"2024"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0007","unstructured":"OHAT risk of bias rating tool for human and animal studies 2015."},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0008","first-page":"19","article-title":"Phase 2 open-label extension (OLE) study of patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis: 24-month safety and efficacy in subgroup of patients with cardiac involvement","volume":"19","author":"Adams","year":"2017","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0009","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-10-S1-O21","article-title":"Phase 2, open-label extension (OLE) study of revusiran, an investigational RNAi therapeutic for the treatment of patients with transthyretin cardiac amyloidosis","volume":"10","author":"Gillmore","year":"2015","journal-title":"Orphanet J Rare Dis"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0010","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10557-019-06919-4","article-title":"Phase 3 multicenter study of revusiran in patients with hereditary transthyretin-mediated (hATTR) amyloidosis with cardiomyopathy (ENDEAVOUR)","volume":"34","author":"Judge","year":"2020","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0011","doi-asserted-by":"crossref","DOI":"10.1042\/BSR20193937","article-title":"Attenuating ischemia\/reperfusion injury in rat cardiac transplantation by intracoronary infusion with siRNA cocktail solution","volume":"40","author":"Yang","year":"2020","journal-title":"Biosci Rep"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0012","doi-asserted-by":"crossref","first-page":"H531","DOI":"10.1152\/ajpheart.00048.2019","article-title":"STAT4 silencing underlies a novel inhibitory role of microRNA-141-3p in inflammation response of mice with experimental autoimmune myocarditis","volume":"317","author":"Pan","year":"2019","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0013","doi-asserted-by":"crossref","DOI":"10.1002\/advs.201900023","article-title":"Effective delivery of hypertrophic miRNA inhibitor by cholesterol-containing nanocarriers for preventing pressure overload induced cardiac hypertrophy","volume":"6","author":"Zhi","year":"2019","journal-title":"Adv Sci"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0014","doi-asserted-by":"crossref","first-page":"7790","DOI":"10.1016\/j.biomaterials.2013.06.051","article-title":"Delivery of Nox2-NADPH oxidase siRNA with polyketal nanoparticles for improving cardiac function following myocardial infarction","volume":"34","author":"Somasuntharam","year":"2013","journal-title":"Biomaterials"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0015","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1007\/s00109-008-0363-x","article-title":"Cardiac-targeted RNA interference mediated by an AAV9 vector improves cardiac function in coxsackievirus B3 cardiomyopathy","volume":"86","author":"Fechner","year":"2008","journal-title":"J Mol Med Berl Ger"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0016","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.108.783852","article-title":"Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy","volume":"119","author":"Suckau","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0017","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1038\/s41434-018-0045-4","article-title":"Long noncoding RNA Meg3 regulates cardiomyocyte apoptosis in myocardial infarction","volume":"25","author":"Wu","year":"2018","journal-title":"Gene Ther"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0018","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1161\/CIRCRESAHA.117.312052","article-title":"Suppression of activated FOXO transcription factors in the heart prolongs survival in a mouse model of laminopathies","volume":"122","author":"Auguste","year":"2018","journal-title":"Circ Res"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0019","doi-asserted-by":"crossref","first-page":"1998","DOI":"10.1093\/cvr\/cvz130","article-title":"Targeting the highly abundant circular RNA circSlc8a1 in cardiomyocytes attenuates pressure overload induced hypertrophy","volume":"115","author":"Lim","year":"2019","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0020","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1517\/21678707.2013.841576","article-title":"Tafamidis for the treatment of transthyretin-associated familial amyloid polyneuropathy","volume":"1","author":"Schmidt","year":"2013","journal-title":"Expert Opin Orphan Drugs"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0022","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1128\/MMBR.67.4.657-685.2003","article-title":"RNA interference: biology, mechanism, and applications","volume":"67","author":"Agrawal","year":"2003","journal-title":"Microbiol Mol Biol Rev MMBR"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0023","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1080\/13543784.2021.1928073","article-title":"RNA therapeutics for mood disorders: current evidence toward clinical trials","volume":"30","author":"Le Marois","year":"2021","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0024","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.jacl.2022.01.001","article-title":"Pharmacokinetics and pharmacodynamics of inclisiran, a small interfering RNA therapy, in patients with hepatic impairment","volume":"16","author":"Kallend","year":"2022","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0025","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.668464","article-title":"miRNA-based therapeutics in breast cancer: a systematic review","volume":"11","author":"Grimaldi","year":"2021","journal-title":"Front Oncol"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0026","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.cardfail.2023.10.302","article-title":"The use of patisiran for the improvement of cardiac parameters in hereditary transthyretin-mediated amyloidosis: a systematic review and meta-analysis","volume":"30","author":"Charles","year":"2024","journal-title":"J Card Fail"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0027","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ncrna.2023.06.002","article-title":"Non-coding RNA therapeutics in cardiovascular diseases and risk factors: systematic review","volume":"8","author":"Ardiana","year":"2023","journal-title":"Non-Coding RNA Res"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0028","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.lfs.2018.11.016","article-title":"A meta-analysis of dysregulated miRNAs in coronary heart disease","volume":"215","author":"Wang","year":"2018","journal-title":"Life Sci"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0029","doi-asserted-by":"crossref","first-page":"4420","DOI":"10.1021\/acsbiomaterials.1c00765","article-title":"Progress of photodynamic and RNAi combination therapy in cancer treatment","volume":"7","author":"Li","year":"2021","journal-title":"ACS Biomater Sci Eng"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0030","doi-asserted-by":"crossref","first-page":"24560","DOI":"10.18632\/oncotarget.4183","article-title":"RNAi therapy targeting KRAS in combination with chemotherapy for locally advanced pancreatic cancer patients","volume":"6","author":"Golan","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0031","unstructured":"An alternating irradiation strategy-driven combination therapy of PDT and RNAi for highly efficient inhibition of tumor growth and metastasis - Yue - 2021 - advanced healthcare materials, Wiley Online Library 2024. https:\/\/onlinelibrary.wiley.com\/doi\/abs\/10.1002\/adhm.202001850 (accessed June 26, 2024)."},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2022.100103","article-title":"New paradigm in combination therapy of siRNA with chemotherapeutic drugs for effective cancer therapy","volume":"3","author":"Kumar","year":"2022","journal-title":"Curr Res Pharmacol Drug Discov"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0033","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1093\/cvr\/cvq056","article-title":"Cardiac-targeted delivery of regulatory RNA molecules and genes for the treatment of heart failure","volume":"86","author":"Poller","year":"2010","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.hrtlng.2024.08.015_bib0034","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1038\/s41569-019-0218-x","article-title":"RNA-based diagnostic and therapeutic strategies for cardiovascular disease","volume":"16","author":"Lu","year":"2019","journal-title":"Nat Rev Cardiol"}],"container-title":["Heart & Lung"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956324001523?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0147956324001523?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,10,10]],"date-time":"2024-10-10T22:21:45Z","timestamp":1728598905000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0147956324001523"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":33,"alternative-id":["S0147956324001523"],"URL":"https:\/\/doi.org\/10.1016\/j.hrtlng.2024.08.015","relation":{},"ISSN":["0147-9563"],"issn-type":[{"value":"0147-9563","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and effectiveness of interference RNA (RNAi) based therapeutics in cardiac failure: A systematic review","name":"articletitle","label":"Article Title"},{"value":"Heart & Lung","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.hrtlng.2024.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}